Stefanos A. Zenios
Graduate School of Business
Littlefield room #236
Stanford, CA 94305-5015
Stefanos Zenios is a professor of operations, information, and technology at the Graduate School of Business, Stanford University and a Stanford Health Policy associate. Professor Zenios studies how health care delivery systems use technology to prolong life and improve its quality for patients with complex and expensive medical needs. He is especially interested in the impact the decisions of providers and payers have on the innovators. Some of the issues he examines include: medical technology adoption through shared decision making between physicians and patients; financial incentives for the adoption and initiation of complex treatments; differences in the utilization of medical technology and outcomes between for-profit and non-profit health care providers; evidence-based decision making and its effect on equitable utilization of medical technology; the value of life implied by existing medical practice and its implications; early-stage business models in medical technology.
Zenios has explored these questions in the context of end-stage organ failure and particularly kidney failure. His research is supported by grants from the NIH, by the prestigious CAREER award from NSF, and by Stanford Hospital and Clinic. He is now expanding his analysis to other conditions such as cardiovascular diseases.
In addition, Zenios teaches two MBA courses:
In Health Care Management and Innovation the students examine the strategic forces that shape market-based health care systems, the quality of care delivered in such systems, and the incentives for innovation.
In Biodesign Innovation, co-taught with Dr Paul Yock and Dr Josh Mackower from the Biodesign Program at Stanford University, interdisciplinary teams of students from the Business School, Medical School, and School of Engineering develop prototypes for medical devices to address important unmet medical needs and business plans to commercialize these products.
He has also consulted extensively companies in the life science sector, helping them redesign their product development and delivery processes in response to shifting market conditions. He is the co-founder of Culmini Inc, an early-stage startup that develops intelligent algorithms for patient customization of complex treatment protocols.